Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination

Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination

Cancer patients (CPs) have been identified as particularly vulnerable to SARS-CoV-2 infection, and therefore are a priority group for receiving COVID-19 vaccination. From the patients with advanced solid tumors, about 20% respond very efficiently to immunotherapy with anti-PD1/PD-L1 antibodies and a...

Full description

Bibliographic Details
Main Authors: Marta Sisteré-Oró, Diana D. J. Wortmann, Naína Andrade, Andres Aguilar, Clara Mayo de las Casas, Florencia Garcia Casabal, Susana Torres, Eduardo Bona Salinas, Laura Raventos Soler, Andrea Arcas, Carlos Esparre, Beatriz Garcia, Joselyn Valarezo, Rafael Rosell, Roberto Güerri-Fernandez, Maria Gonzalez-Cao, Andreas Meyerhans
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Immunology
Subjects:
COVID-19 vaccination
mRNA-based vaccines
cancer
SARS-CoV-2
long lasting responders
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.908108/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.908108/full

Similar Items